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Abstract
Background: It has recently been shown that overexpression of the serine protease, matriptase, in transgenic mice causes a
dramatically increased frequency of carcinoma formation. Overexpression of HAI-1 and matriptase together changed the
frequency of carcinoma formation to normal. This suggests that the ratio of matriptase to HAI-1 influences the malignant
progression. The aim of this study has been to determine the ratio of matriptase to HAI-1 mRNA expression in affected and
normal tissue from individuals with colorectal cancer adenomas and carcinomas as well as in healthy individuals, in order to
determine at which stages a dysregulated ratio of matriptase/HAI-1 mRNA is present during carcinogenesis.
Methods: Using quantitative RT-PCR, we have determined the mRNA levels for matriptase and HAI-1 in colorectal cancer tissue
(n = 9), severe dysplasia (n = 15), mild/moderate dysplasia (n = 21) and in normal tissue from the same individuals. In addition,
corresponding tissue was examined from healthy volunteers (n = 10). Matriptase and HAI-1 mRNA levels were normalized to β-
actin.
Results: Matriptase mRNA level was lower in carcinomas compared to normal tissue from healthy individuals (p < 0.01). In
accordance with this, the matriptase mRNA level was also lower in adenomas/carcinomas combined as compared to their
adjacent normal tissue (p < 0.01). HAI-1 mRNA levels in both normal and affected tissue from individuals with severe dysplasia
or carcinomas and in affected tissue with mild/moderate dysplasia were all significantly lower than mRNA levels observed in
corresponding tissue from healthy control individuals. HAI-1 mRNA was lower in carcinomas as compared to normal tissue
from healthy individuals (p < 0.001). HAI-1 mRNA levels were significantly lower in tissue displaying mild/moderate (p < 0.001)
and severe (p < 0.01) dysplasia compared to normal tissue from the same patients. Both adenomas and carcinomas displayed a
significantly different matriptase/HAI-1 mRNA ratio than corresponding normal tissue from healthy control individuals (p < 0.05).
In addition statistically significant difference (p < 0.001) could be observed between mild/moderate and severe adenomas and
their adjacent normal tissue.
Conclusion: Our results show that dysregulation of the matriptase/HAI-1 mRNA ratio occurs early during carcinogenesis.
Future studies are required to clarify whether the dysregulated matriptase/HAI-1 ratio was causing the malignant progression or
is a consequence of the same.
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Background
Matriptase also known as MT-SP1, epithin, TADG-15 and
SNC19, is the prototypic member of a recently identified
matriptase subfamily of type II transmembrane serine
proteases together with matriptase-2 and matriptase-3 [1-
7]. It has a multi-domain structure, including an amino-
terminal cytoplasmic tail, a transmembrane region, a
sperm protein, enterokinase, and agrin (SEA) domain,
two complement subcomponents C1r/Cs, urchin embry-
onic growth factor and bone morphogenic protein (CUB)
domain, four low density lipoprotein receptor class A
repeats, and a carboxyl-terminal serine protease domain
[1,2,4,8]. Matriptase is required for postnatal survival [9]
and is essential for processing of pro-filaggrin which is
important for epidermal differentiation [10]. Matriptase is
co-expressed with its cognate inhibitor, hepatocyte
growth factor activator inhibitor 1 (HAI-1) in many types
of normal and malignant tissues of epithelial origin [11-
14]. HAI-1 is a type 1 integral membrane, Kunitz-type ser-
ine protease inhibitor [15] and contains two Kunitz
domains and a low density lipoprotein receptor class A
domain. HAI-1 knock-out mice die during the embryonic
development [16].
It has recently been shown that matriptase possesses a
strong oncogenic potential since even a modest overex-
pression in the skin of transgenic mice caused 100% of the
mice to develop tumors, 70% of which progressed into
carcinomas [17]. Increased expression of HAI-1, com-
pletely negated the oncogenic effects of matriptase overex-
pression [17]. These data strongly suggest that a
dysregulated ratio of matriptase to HAI-1 causes malig-
nant transformation to occur at a high frequency whereas
aberrant expression of matriptase or HAI-1 per se does not
seem to be important.
Several studies suggest that matriptase is over-expressed in
a wide variety of malignant tumors including prostate,
ovarian, uterine, colon, epithelial-type mesothelioma and
cervical cell carcinoma [4,12,18-22]. It has also been
reported that HAI-1 is over-expressed in breast cancer
[23]. However, none of these studies has focused on the
ratio of matriptase/HAI-1 expression.
Prompted by the finding that a dysregulated ratio of
matriptase to HAI-1 in mice results in tumor formation
and carcinogenesis, we have analysed the ratio of
matriptase/HAI-1 mRNA expression during colorectal
cancer carcinogenesis in humans.
Methods
Subject population
The KAM cohort (Kolorektal cancer, Arv og Miljø) is based
on the screening group of the Norwegian Colorectal Can-
cer Prevention study (The NORCCAP study) in the county
of Telemark, Norway [24]. The ID number for the NORC-
CAP study at Clinicaltrials.gov is [I NCT00119912] [25].
A total of 20,780 men and women, age distribution 50–
64 years, drawn randomly from the population registries
in Oslo (urban) and the county of Telemark (mixed urban
and rural) were invited to have a flexible sigmoidoscopy
screening examination with or without (1:1) an addi-
tional faecal occult blood test (FOBT). 777 individuals
were excluded according to exclusion criteria [26]. The
KAM biobank currently consists of 170 colorectal cancer
cases, 991 cases with adenomas, and 400 controls. Con-
trols were defined as individuals with normal findings at
the flexible sigmoidoscopy screening. The colorectal can-
cer cases of the KAM biobank consist of patients operated
on at Telemark Hospital and Ulleval University Hospital
in Oslo. The KAM study is approved by the Regional Eth-
ical Committee and the Norwegian Data Inspectorate. In
the present study we have analyzed cases with carcinomas
(n = 9), cases with adenomas (n = 36) and controls that
were polyp free in the screened region of the colon (n =
10). From individuals with adenomas a sample of control
tissue was collected 30 cm from anus. From patients with
carcinomas, a sample of control tissue was taken from the
surgically removed tissue, as far away from the tumor as
possible. Control samples from healthy individuals were
taken from individuals where no adenomas or carcino-
mas could be identified with flexible sigmoidoscopy. The
histology of the adenomas was examined independently
by two specialist histopathologists in order to determine
the tumor stage as either mild/moderate (n = 21) or severe
(n = 15). They reached the same conclusion in all cases.
The distribution of gender and age among cases with
colonic carcinomas and adenomas and controls are
shown in Table 1. One case with mild/moderate dysplasia
showed no detectable mRNA for either β-actin, matriptase
and HAI-1 and was therefore excluded from the study.
Individuals with dysplasia, who developed carcinomas
and were treated at the same hospital, were registered.
RT-PCR
Total RNA was purified from tissue as recommended by
the manufacturers using Qiagen kit (AH diagnostics,
Aarhus, Denmark). The tissue had been stored in liquid
N2 before RNA purification. RNA purification included a
DNAse treatment. The cDNA synthesis was performed on
approximately 200 ng RNA per 10 μl using Gold RT-RCR
kit (Applied Biosystems, Nærum, Denmark). Quantitative
RT-PCR was performed on ABI7500 sequence detection
system (Applied Biosystems) in Universal Mastermix
(Applied Biosystems) using 160/140 nM probe and 600/
300 nM primers for matriptase  and HAI-1, respectively.
Matriptase: primers were matrip F,
5'GCGCTCCCTGAAGTCCTTT3'; matrip R
5'GTCCTGGGTCCTCTGTACTGTTTT3'; probe, matrip t
5'FAM-TCACCTCAGTGGTGGCTTTCCCCA-BHQ-1-3'.BMC Cancer 2006, 6:176 http://www.biomedcentral.com/1471-2407/6/176
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HAI-1: primers were HAI 1 1532F
5'CGCGGCATCTCCAAGAAG3'; HAI 1 1651R
5'GAACACTGCGACAGCCATCTC3'; probe, HAI 1 1572T
5'FAM-AAATCCCCATTCCCAGCACAGGCTC-BHQ-1-3'.
The HAI-1 primers detects both HAI-1 and the splice vari-
ant HAI-1B. Primers were designed using Primer Express
v2.0 Software. Primers were designed within different
exons and with probes covering the exon-exon border to
prevent amplification of genomic DNA. 18S rRNA and β-
actin primers and probes were obtained from Applied Bio-
systems. Matriptase and HAI-1 primers and probes were
obtained from TAC Copenhagen. In a validation experi-
ment using a control sample, a dilution series was pro-
duced and assayed for matriptase, HAI-1 and β-actin as
described for the comparative Ct method [27]. When plot-
ted it could be shown that the assays are quantitative over
a range of 512-fold dilution for both matriptase and HAI-
1 and that the PCR reactions have similar efficiencies pro-
vided that a threshold of 0.2 is used for matriptase and β-
actin while the threshold was 0.025 for HAI-1. The thresh-
old is a fixed fluorescence signal level above the baseline.
The Ct value of a sample is determined as the fractional
cycle number when the samples fluorescence signal
exceeds the threshold. The threshold is thus assay specific,
determined in the validation experiment and depends on
the background of the individual assay. This implies that
even though the amplification curves for matriptase and
HAI-1 were overlapping, indicating that the two genes had
the same relative abundance, the normalised HAI-1
mRNA level seemed higher due to the lower threshold
used.
Matriptase, HAI-1, β-actin and 18S were quantified sepa-
rately in triplicates. The average standard deviation on
triplicates was 6%. The standard deviation on repeated
measurements of the same sample (the control) in sepa-
rate experiments was 8% and 14% for matriptase and HAI-
1 respectively, indicating the day-to-day variation of the
assay. Independent PCR reactions of the same samples
yielded a correlation coefficient of 0.88. Negative controls
(where the RNA was not converted into cDNA) and posi-
tive controls were included in all sets. Essentially the same
results were obtained whether the expression was normal-
ised to β-actin or 18S (correlation coefficient of 0.921).
Statistical analysis
MiniTab Statistical Software, Release 13.1 Xtra (Minitab
Inc.) and GraphPad Prism 4 were used for the statistic cal-
culations. The data were not adjusted for sex since the
incidence ratio of colorectal cancer between the genders is
1.1 in Norway [28].
Results
The mRNA levels of matriptase and HAI-1 were measured
in colon tissue samples from healthy control individuals
(n = 10) and in healthy and affected tissue from individu-
als with mild/moderate dysplasia (n = 21), with severe
dysplasia (n = 15) and with colorectal cancer (n = 9) by
real-time RT-PCR. We chose to normalise the mRNA levels
of  matriptase  and  HAI-1  to the mRNA level of β-actin.
Essentially identical results were obtained when normal-
ized to 18S rRNA (see material and methods). We found
that matriptase, HAI-1 and β-actin mRNA's are present with
almost the same abundances (Fig. 1 and Table 2) within
one order of magnitude. This shows that the mRNA's of
matriptase and HAI-1 are relative abundant.
The range and the interquartile range of mRNA expression
of matriptase and HAI-1 normalised to β-actin are shown
in Figure 1. The matriptase mRNA level tended to decrease
with increasing tumor grade both in dysplastic and can-
cerous tissue as well as in normal tissue from the same
individuals. When the matriptase mRNA level of healthy
individuals was compared with colorectal cancer tissue, a
Table 1: Characteristics of cases and healthy persons used in this study
Healthy Cases
Adenomas1 Carcinomas
Mild/moderate Dysplasia Severe dysplasia
(n = 10) (n = 20) (n = 15) (n = 9)
Men2 41 5 1 37
Women2 6522
Mean age + SD3 54.1 ± 3.4 59.1 ± 3.1 58.4 ± 4.3 61.67 ± 9.1
1The adenomas are divided in groups according to diagnosed degree of dysplasia (mild/moderate or severe).
2There were significantly more males in the group with severe dysplasia compared to the group of healthy individuals (p = 0.014). There was no 
significant difference in the number of males and females between the group of healthy individuals and the group with mild/medium dysplasia or 
between the group of healthy individuals and the group with carcinomas (χ2 test).
3There are significant differences in age among the four groups of healthy and affected individuals at 95% confidence level. There is no significant 
difference in age between the three case groups (Mann-Whitney test).BMC Cancer 2006, 6:176 http://www.biomedcentral.com/1471-2407/6/176
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statistically significant decrease (p < 0.01) was observed
(Table 2 and Fig. 1). Also the matriptase mRNA level of all
adenomas and carcinomas combined were statistically
significantly lower than the corresponding level in healthy
tissue from the same individuals (p < 0.01) (Table 2).
HAI-1  displayed a stronger general decrease in mRNA
level with increasing tumor grade for both dysplastic and
cancerous tissues as well as in normal tissue than
matriptase (Fig. 1). A decrease of 65% was seen in carcino-
mas as compared to corresponding tissue in healthy con-
trol individuals. When comparing the expression level of
HAI-1 in dysplastic and cancerous tissue with correspond-
ing tissue from healthy individuals, statistically significant
lower expression was encountered (p < 0.001) (Table 2)
in all groups. There was also a statistically significant dif-
ference between normal tissue from healthy individuals
and normal tissue from individuals with severe dysplasia
and carcinomas (p < 0.05). When comparing affected tis-
sue, with normal tissue from the same individual, we
found a statistically significant difference for individuals
with mild/moderate dysplasia (p < 0.001) and severe dys-
plasia (p < 0.01). No statistically significant difference was
seen in carcinoma tissue compared to unaffected tissue
from the same person (Table 2). A comparison of all ade-
nomas and carcinomas combined, with normal tissues
from the same person also showed a statistically signifi-
cant difference (p < 0.001).
It has recently been shown that is was not the expression
of matriptase per se but the ratio of matriptase/HAI-1
expression that determines the frequency of carcinoma
formation in a mouse model [17]. We therefore investi-
gated the ratio of matriptase/HAI-1 mRNA expression dur-
ing colorectal carcinogenesis (Figure 1 and Table 2). We
found a statistically significant higher ratio of matriptase/
HAI-1 mRNA levels in tissue with both mild/moderate
dysplasia (p < 0.05), severe dysplasia (p < 0.05) and in
carcinomas (p < 0.05) when compared to corresponding
tissue from healthy individuals. When compared to the
ratio of matriptase/HAI-1 mRNA in normal tissue from the
same individual there was a statistically significant differ-
ence for mild/moderate dysplasia (p < 0.001), for severe
dysplasia (p < 0.001) and for all adenomas and carcino-
mas combined (p < 0.001). No statistically significant dif-
ference was seen in carcinoma tissue compared to
unaffected tissue from the same person (Table 2). Thus
more unopposed matriptase is present in dysplastic and
cancerous tissue than in corresponding tissue from
healthy control individuals.
Four individuals with either mild/moderate and/or severe
dysplasia later developed colorectal cancer during follow-
up. The matriptase/HAI-1 mRNA levels in the tissue dis-
playing dysplasia of these individuals are shown in Table
The mRNA expression of matriptase, HAI-1 and the ratios  between matriptase/HAI-1 mRNAs determined by real-time  RT-PCR from healthy individuals (N), individuals with mild/ moderate dysplasia (M/M), severe dysplasia (S) or carcinomas  (C) Figure 1
The mRNA expression of matriptase, HAI-1 and the 
ratios between matriptase/HAI-1 mRNAs determined 
by real-time RT-PCR from healthy individuals (N), 
individuals with mild/moderate dysplasia (M/M), 
severe dysplasia (S) or carcinomas (C). Both normal 
(open bars) and affected (hatched bars) tissue were exam-
ined from each individual. Both mRNA levels were normal-
ized to the β-actin mRNA level. The box shows the 
interquartile range, the whiskers the range and the median is 
indicated by a vertical line.
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3. These individuals did not have higher matriptase/HAI-1
ratios than the average in their group.
Discussion
In the present study we have determined the mRNA levels
of matriptase and HAI-1 during colorectal cancer carcino-
genesis. It has previously been shown that there is a good
correlation between mRNA levels and protein levels for
matriptase [12,18,20] and HAI-1 [12].
It has previously been described that matriptase is up-reg-
ulated in various human carcinomas by factors of 5–600
[4,12,14,18,19,22,29] and in prostatic tissue with a mod-
est up-regulation [21]. This is in contrast to the present
study where we observe a modest but significant 30%
down-regulation of matriptase mRNA in carcinomas com-
pared to corresponding tissue in healthy individuals. In a
very recent study it was reported that matriptase mRNA is
down-regulated in both gastric and colorectal cancer as
compared to adjacent normal tissue [30]. This is in agree-
ment with our observations as the matriptase mRNA level
tended to decrease with increasing tumor grade.
Table 3: The matriptase/HAI-1 ratio of individuals with mild/moderate or severe dysplasia who later developed carcinomas. The mRNA 
levels were normalised to β-actin mRNA levels.
Matriptase/HAI-1 ratio
KAM ID no. Mild/moderate Severe
278 0.124 0.100
344 0.115
803 0.121
193 0.146
Mean (SD)* 0.132(0.044) 0.142(0.044)
*Mean (SD) of their group also listed in Table 2.
Table 2: Matriptase and HAI-1 mRNA levels in normal and affected tissues. The mRNA levels were normalised to β-actin mRNA levels.
Variable mRNA level in normal 
tissue Mean (SD)
Pa mRNA level in 
adenomas/carcinomas 
Mean (SD)
Pa Pb
Matriptase
Healthy people 0.93 (0.18)
Mild/moderate 1.02 (0.23) NS 0.86 (0.31) NS NS
Severe 0.74 (0.22) NS 0.66 (0.24) NS NS
Carcinoma 0.66 (0.36) NS 0.49 (0.25) <0.01 NS
All adenomas and 
carcinomas
0.85 (0.29) ND 0.72 (0.31) ND <0.01
HAI-1
Healthy people 12.84 (3.70)
Mild/moderate 16.35 (5.22) NS 7.35 (3.67) <0.001 <0.001
Severe 7.55 (2.12) <0.05 4.93 (1.83) <0.001 <0.01
Carcinoma 7.17 (4.79) <0.05 4.26 (2.25) <0.001 NS
All adenomas and 
carcinomas
11.47 (6.23) ND 5.89 (3.14) ND <0.001
Matriptase/HAI-1 
ratio
Healthy people 0.076 (0.018)
Mild/moderate 0.067 (0.024) NS 0.132 (0.044) <0.05 <0.001
Severe 0.102 0.027) NS 0.142 (0.044) <0.05 <0.001
Carcinoma 0.095 (0.036) NS 0.144 (0.084) <0.05 NS
All adenomas and 
carcinomas
0.085 (0.032) ND 0.138 (0.053) ND <0.001
NS = not significant, ND = not determined
a) p value for the comparison to the expression levels in healthy persons using a one-way ANOVA and Tukey's post test for paired comparisons.
b) p value for the comparison of the expression levels in normal and affected tissue from the same person using a paired T-testBMC Cancer 2006, 6:176 http://www.biomedcentral.com/1471-2407/6/176
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Since it was recently shown that in mice it is not the
matriptase expression per se, but the amount of HAI-1
unopposed matriptase that determined the frequency of
malignant transformation [17] we also examined the
expression of HAI-1  mRNA. We found a significant
decrease of HAI-1 mRNA in tissue with mild/moderate
dysplasia and in affected and normal tissue from individ-
uals with severe dysplasia and carcinomas as compared to
corresponding tissue from healthy control individuals. A
HAI-1 down regulation has previously been described in
renal cell carcinomas as compared to corresponding nor-
mal tissue from control individuals [31]. Recently it was
also shown that HAI-1 mRNA level is down-regulated in
gastric and colorectal cancer as compared to adjacent nor-
mal tissue [30]. This agrees well with our findings as also
the HAI-1 mRNA level tended to decrease with increasing
tumor grade.
When examining the ratio of matriptase to HAI-1 mRNA a
significant altered ratio was found in affected tissue dis-
playing mild/moderate dysplasia, severe dysplasia and in
carcinomas as compared to corresponding tissue from
control individuals. This means that more HAI-1 unop-
posed matriptase is present in in dysplastic and cancerous
tissue, which in a mouse model has been shown to give a
increased frequency of malignant transformation [17]. We
did not observe any statistically significant differences
between normal tissue from healthy individuals and unaf-
fected tissue from individuals with adenomas or carcino-
mas, although HAI-1  mRNA level was statistically
significantly lower in normal tissue from individuals with
severe dysplasia and carcinomas compared to the level
found in healthy persons. A larger number of cases should
be studied in order to determine whether the matriptase/
HAI-1 ratio is dysregulated in unaffected tissue from indi-
viduals with severe dysplasia and carcinomas. In agree-
ment with our study it was recently reported that the
matriptase /HAI-1 mRNA ratio is not significantly different
in colorectal cancer compared to adjacent normal tissue
[30].
Collectively, this suggests that the dysregulated ratio
between matriptase and HAI-1 can arise either by up reg-
ulation of the matriptase expression or by down regula-
tion of the HAI-1 expression, or by a combination of the
two depending on the type of cancer. Our data further
suggest that the disturbance of the matriptase/HAI-1 ratio
is an early event in colorectal cancer carcinogenesis as it is
already present in tissue displaying mild/moderate dys-
plasia and that the dysregulation is maintained during all
stages of malignant progression. It is interesting to note
that even though both matriptase and HAI-1 is down regu-
lated in colorectal cancer, a similar down regulation takes
place in the adjacent normal tissue resulting in an
unchanged matriptase/HAI-1 mRNA ratio.
It is at present unclear how a dysregulated matriptase/
HAI-1 ratio is connected to carcinogenesis as the biologi-
cal function of matriptase is not well understood. It is
known that matriptase is essential for processing of pro-
filaggrin [10], but this is unlikely to be connected to its
role during carcinogenesis. It is also known that
matriptase can activate pro-urokinase, protease-activator
receptor-2 and hepatocyte growth factor [8,32]. Whether
this is important for the ability of unopposed matriptase
to cause carcinomas is not clear [17].
The acquisition of the ability to invade surrounding tissue
is a key event in carcinogenesis. Proteases are believed to
play a crucial role in this process since dissolution of the
extracellular matrix is a prerequisite for invasive growth
and metastatic spread of tumor cells. Matriptase is possi-
bly involved in this as the serine protease is expressed by
the tumor cells themselves and CVS-3983, a matriptase
inhibitor, has been developed and shown to retard tumor
growth in a human prostate cancer xenograft model [33].
HAI-1 may play an importent role as it has been shown
that HAI-1 at the invasive front of colorectal adenocarci-
nomas is most often in a mature, membrane-bound form,
whereas ectodomain shedding is common in the rest of
the tumor [34].
Interestingly, it was shown that even a modest dysregu-
lated matriptase expression strongly potentiates chemical
carcinogenesis in mice [17]. It was shown that matriptase
induced spontaneous carcinoma formation that occurs
independently of ras mutations, whereas carcinogen-
induced tumors often are accompanied by H-ras or K-ras
mutations. The dysregulated matriptase/HAI-1 ratio
observed in mild/moderate and severe dysplasia may pro-
mote carcinogenesis by potentiating chemical carcinogen-
esis, and may thus be one of the underlying reasons why
polyps transform into carcinomas.
Our results have shown that the abundance of the
matriptase and HAI-1 mRNA are similar to each other and
to that of β-actin within one order of magnitude. How-
ever, it has previously been shown that matriptase protein
is present in very low levels in both normal and malignant
epithelium (2–24 ng matriptase pr mg detergent-extracta-
ble protein) [12]. Likewise HAI-1 is not an abundant pro-
tein in mouse intestine (Vogel., L.K unpublished results).
This may indicate that these proteins have a short half-life
compared to β-actin or that the translation frequency of
the mRNAs is low. Indeed the half life of HAI-1 when
recombinantly expressed in MDCK cells is in the range of
a 1.5 hour (Godiksen, S. and Vogel, L.K., unpublished
data).BMC Cancer 2006, 6:176 http://www.biomedcentral.com/1471-2407/6/176
Page 7 of 8
(page number not for citation purposes)
Conclusion
In conclusion, our study shows that dysregulation of the
matriptase/HAI-1 mRNA ratio as compared to the corre-
sponding tissue in healthy control individuals, is an early
event in colorectal cancer carcinogenesis that is main-
tained during all stages of malignant progression. Future
studies are required to clarify whether the dysregulated
matriptase/HAI-1 ratio was causing the malignant progres-
sion or is a consequence of the same.
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